SONOVA HOLDING-UNSPON ADR Business Summary

Sonova Holding AG (SONVY) is a vertically integrated global leader in hearing care, generating revenue through the wholesale distribution of hearing aids and direct-to-consumer services via a retail network of approximately 3,900 clinics. The company operates through two primary business segments: Hearing Instruments, which includes the flagship Phonak and Unitron brands, and Cochlear Implants, managed under the Advanced Bionics brand. In March 2026, Sonova initiated a strategic divestment of its Consumer Hearing business (Sennheiser brand) to focus exclusively on medical-grade hearing solutions and AI-enabled audiological innovation, exemplified by its Infinio technology platform. Sonova maintains a dominant market position against primary competitors Demant, WS Audiology, and GN Store Nord, distinguishing itself through superior R&D investment and a comprehensive multi-brand, multi-channel distribution strategy. Originally founded in 1947 as AG für Elektroakustik, the company’s modern trajectory was shaped by Ernst Rihs, Beda Diethelm, and Rihs’ sons, Andy and Hans-Ueli Rihs, who transformed it into a global powerhouse. The current leadership team is headed by CEO Eric Bernard, who joined in 2025 from WS Audiology, and CFO Elodie Carr-Cingari, formerly of Landis+Gyr. The Board of Directors is chaired by Gilbert Achermann, the former long-time leader of Straumann Group, and includes notable independent members such as Hooi Ling Tan (co-founder of Grab) and Malina Ngai. Significant equity remains held by the founding Diethelm and Rihs families, alongside institutional investors including BlackRock and UBS Fund Management, ensuring a stable governance structure focused on long-term profitable growth.